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ABSTRACT
Transplantation of cells within alginate microspheres has been extensively studied for sustained drug
delivery. However, the lack of control over cell behavior represents a major concern regarding the effi-
cacy and the safety of the therapy. Here, we demonstrated that when formulating the biosystem, an
adequate selection of osmolarity adjusting agents significantly contributes to the regulation of cell
responses. Our data showed that these agents interact in the capsule formation process, influencing
the alginate crosslinking degree. Therefore, when selecting inert or electrolyte-based osmolarity adjust-
ing agents to encapsulate D1 multipotent mesenchymal stromal cells (MSCs), alginate microcapsules
with differing mechanical properties were obtained. Since mechanical forces acting on cells influence
their behavior, contrasting cell responses were observed both, in vitro and in vivo. When employing
mannitol as an inert osmolarity adjusting agent, microcapsules presented a more permissive matrix,
allowing a tumoral-like behavior. This resulted in the formation of enormous cell-aggregates that pre-
sented necrotic cores and protruding peripheral cells, rendering the therapy unpredictable, dysfunc-
tional, and unsafe. Conversely, the use of electrolyte osmolarity adjusting agents, including calcium or
sodium, provided the capsule with a suitable crosslinking degree that established a tight control over
cell proliferation and enabled an adequate therapeutic regimen in vivo. The crucial impact of these
agents was confirmed when gene expression studies reported pivotal divergences not only in prolifera-
tive pathways, but also in genes involved in survival, migration, and differentiation. Altogether, our
results prove osmolarity adjusting agents as an effective tool to regulate cell behavior and obtain safer
and more predictable therapies.
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The entrapment of therapeutically active cells within alginate
microspheres has been widely employed for the sustained
delivery of therapeutics (Strand et al., 2017). The long-term
function of the system allows the continuous production of
therapeutics, avoiding the necessity of frequent administra-
tions and hence, improving patient’s quality of life. However,
the performance of the system is directly dependent on cell
responses and nowadays implant functionality and safety are
still importantly limited by a lack of control over cell behavior
(Santos et al., 2013). Among the erratic cell responses,
excessive proliferation rates represent one of the major hur-
dles, especially when it comes to using immortalized cell
lines (Bhujbal et al., 2014). Cellular overgrowth results in
aggregates that present a characteristic dualism. On the one
hand, the limited diffusion of nutrients and oxygen to the core
of the aggregates results in inner cell death (de Vos, 2017).
This does not only lead to a diminished therapeutic effect, but
has additional consequences, since intracellular components
derived from dying cells, namely danger-associated molecular
patterns (DAMPs), function as alarm molecules that evoke
important immune and inflammatory responses (Paredes
Juarez et al., 2014). On the other hand, protruding peripheral
cells may leak out of the matrix, constituting a major safety
concern (Bhujbal et al., 2014).
In attempting to develop systems with improved control
over cell behavior, tuning the mechanical properties of the
matrix has been suggested as a valuable strategy. This is
possible because of the mechanotransduction process, by
which mechanical forces acting on cells influence their bio-
chemical behavior and viability (Humphrey et al., 2014).
Taking advantage of it, we focused on osmolarity adjusting
agents as a tool to modify the mechanics of the capsule and
therefore, regulate cell behavior. The process of cell encapsu-
lation requires the dissolution of the employed biomaterials.
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Therefore, to meet the standards of cell culture, the solutions
of, e.g. alginate or poly-L-lysine (PLL) should present physio-
logical osmolarity values between 260 and 320 mOsm/L
(Ozturk & Palsson, 1991). To this end, osmolarity adjusting
agents are included in the solutions, which can be classified
as electrolyte or inert agents. Considering that microspheres
are ionically crosslinked matrices, the presence or absence of
electrolytes, especially divalent cations, may influence the
capsule formation process. Therefore, the use of different
types of osmolarity adjusting agents may alter the mechan-
ical properties of the matrix, having an impact on cell
responses. To the best of our knowledge, the effect of these
agents in cell behavior and consequently, in the outcome of
the therapy, has not been previously studied in depth.
Here, we designed two sets of solutions (each one includ-
ing all the solutions required for the elaboration of microcap-
sules: 1.5% alginate, 0.05% PLL, 0.1% alginate and washing
solutions), which differed in the selected type of osmolarity
adjusting agent. The biological set contained electrolytes
including calcium, sodium, or phosphates and the techno-
logical was based on mannitol as an inert agent. These solu-
tions were used to encapsulate D1 multipotent mesenchymal
stromal cells (MSCs). MSCs were genetically modified to
express erythropoietin (EPO), a model therapeutic molecule
that can be easily traced in vivo through hematocrit
measurements to assess the functionality of the implant. The
resulting biological and technological microcapsules were
characterized and our data showed that the distinct
mechanical properties of the matrix influenced cells at a
genic level. This resulted in a contrasting cell behavior, which
led to divergent therapeutic profiles in vitro and in vivo, high-
lighting the pivotal importance of an accurate formulation to
obtain systems with suitable properties that control cell
behavior.
2. Methods
2.1. Characterization of the solutions
For characterization, pH was determined by means of the pH-
Meter GLP 21 (CrisonVR , Barcelona, Spain). Osmotic pressure
was assessed by using a cryoscopic osmometer (Osmomat
030, GonotecVR , Berlin,Germany). This type of osmometer
measures the freezing point depression, which is directly pro-
portional to the concentration of osmotically active com-
pounds in aqueous solutions. To calibrate the osmometer,
NaCl calibrating solution was employed. Prior to the measure-
ment, its osmolarity value was set in the osmometer.
Subsequently, 50 mL of the calibrating solution were pipetted
into a clean, dry measuring vessel. After ensuring there were
no visible air bubbles, the measurement was performed and
the result was automatically adopted as the calibration value.
Next, sample measurements were performed under the same
conditions. Each sample was assayed in triplicate.
2.2. Cell culture
MSCs (ATCCVR CRL 12424TM, Manassas, VA) were genetically
modified with the lentiviral vector pSIN-EF2-Epo-Pur to
express EPO (D1-MSCs-EPO) (Gurruchaga et al., 2015). Cells
were seeded in T-flasks and grown in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal
bovine serum (FBS), and 1% (v/v) penicillin/streptomycin.
They were maintained at 37 C in a 5% CO2/95% air atmos-
phere and passaged every 2–3 d using trypsin-EDTA. All
reagents were purchased from Fisher Scientific, Madrid,
Spain.
2.3. Cell microencapsulation
D1-MSCs-EPO were encapsulated using an electrostatic drop-
let generator (NiscoVR , Duluth, GA), following the procedure
designed by Lim and Sun (Lim & Sun, 1980). Briefly, cells
were suspended in 1.5% (w/v) sodium alginate obtaining a
cell density of 5 106 cells/mL. This suspension was extruded
through a 0.35mm needle at a 5.9mL/h flow rate by means
of a peristaltic pump. Beads were collected in a 100mM
CaCl2 bath and maintained in agitation for 10min to ensure
a complete ionic gelation. After washing the particles, they
were suspended in 0.05% (w/v) PLL for 5min. Once washed,
a second coating was performed by suspending the particles
in 0.1% (w/v) alginate for 5min, giving rise to alginate-poly-
L-lysine-alginate (APA) microcapsules. Since different solu-
tions of 1.5% alginate, 0.05% PLL, 0.1% alginate and wash-
ings were designed, three types of APA microcapsules were
obtained: Biological microcapsules (made of biological solu-
tions), technological microcapsules (made of technological
solutions), and hybrid microcapsules (made of biological
1.5% alginate and technological 0.05% PLL, 0.1% alginate
and washing solutions) (Supplementary Figure S1). This last
group was intended for the structural studies, to determine
the influence of core and coating solutions separately in the
final properties of the capsule. Regarding the 100mM CaCl2
bath, the same solution was employed for every group, since
the presence of the gelling ion Caþ2 was mandatory.
Microcapsules were cultured in complete medium at 37 C in
a 5% CO2/95% air atmosphere. All the process was carried
out under aseptic conditions at room temperature. Ultra-pure
low-viscosity high guluronic acid alginate (UPLVG, code
#4200006) was purchased from FMC Biopolymer, Sandvika,
Norway and PLL (hydrobromide Mw 15,000–30,000Da, code
P7890-500MG) from Sigma-Aldrich, Madrid, Spain.
2.4. Cell aggregate area quantification
Micrographs were obtained by an inverted microscope
(Nikon TMS, Hampton, NH) and processed by means of
ImageJ software (Rasband, W.S., ImageJ, US National
Institutes of Health, Bethesda, Rockville, MD, https://imagej.
nih.gov/ij/, 1997–2016) to quantify the cell-aggregate area.
For each time point, aggregates of at least 20 random capsu-
les were analyzed.
2.5. Cell proliferation: bromodeoxyuridine (BrdU) uptake
BrdU uptake was determined by means of Cell Proliferation
Biotrak ELISA System (code GERPN250, Sigma Aldrich,
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Madrid, Spain) in five independent samples per group. In a
96 well-plate, the equivalent of 2 104 cells was placed in
each well (80 microcapsules). All groups were incubated for
24 h in complete medium supplemented with 10% FBS,
except for the starving control group, which was incubated
in medium supplemented with 0.1% FBS. An additional 24-h
incubation was carried out in presence of 10 lM BrdU, except
for the nonspecific binding control group, in which the
reagent was not added. Subsequently, cells were de-encapsu-
lated by means of a 500 lg/mL solution of alginate lyase
(code A1603, Sigma-Aldrich, Madrid, Spain) and the assay
was performed following manufacturer’s indications.
Absorbance measurements were normalized with the non-
specific binding control.
2.6. Viability assays
Three different assays were performed to evaluate the viabil-
ity of the immobilized cells: live/dead staining, flow cytome-
try, and cell metabolism studies. For live/dead staining 10 mL
of microcapsules containing D1-MSCs-EPO were dyed with
the LIVE/DEADVR kit (code L3224, Fisher Scientific, Madrid,
Spain) following manufacture’s indications. After 30min,
fluorescence micrographs were taken using an epi-fluores-
cence microscope (Nikon TSM, Hampton, NH). At least six
independent experiments were analyzed for each group.
For flow cytometry (BD FACS Calibur, San Jose, CA), cells
were de-encapsulated using a 500 lg/mL solution of alginate
lyase. Cells were then treated with trypsin-EDTA to eliminate
possible cell-aggregates and dyed with the LIVE/DEADVR kit.
After 20-min incubation, protected from light and at room
temperature, cells were acquired. Three independent samples
of cells from each group were assayed.
Metabolic activity was determined using the Cell Counting
Kit-8 (CCK-8) (code 96992-3000TESTS-F, Sigma Aldrich,
Madrid, Spain). Approximately 50 microcapsules ( 12,300
cells) were suspended in 100 lL of DMEM and placed in a 96-
well plate. Subsequently, 10 lL of CCK-8 were added to each
well. Plates were incubated for 4 h at 37 C and read on an
Infinite M200 TECAN plate reader (GMI Inc., Ramsey, MN) at
450 nm, with reference wavelength at 650 nm. At least seven
independent experiments were analyzed for each group.
2.7. EPO secretion
EPO secretion was determined by means of the Quantikine
IVD Human EPO ELISA Kit (code DEP00, R&D Systems, Madrid,
Spain). 100 lL of microcapsules were incubated for 24 h at
37 C and supernatants were assayed. Samples and standards
were run in duplicate following manufacturer’s instructions.
Per study group three independent samples were assayed.
2.8. Diameter determination and osmotic resistance test
Micrographs were obtained by an inverted microscope and
analyzed using the ImageJ software. To evaluate osmotic
resistance 100 lL of microcapsules were suspended in 1mL
of deionized water (ddH2O) and placed in 12 well plates.
After 5min, supernatants were replaced with fresh ddH2O to
perform a second washing. The process was repeated to a
total of five washings. Micrographs were taken previous to
the assay and after each washing to determine diameter and
integrity of the capsules. At least 30 microcapsules were ana-
lyzed in both assays.
2.9. Fluorescein isothiocyanate (FITC)-dextran diffusion
In order to determine the microcapsule membrane molecular
weight cutoff (MWCO), FITC-dextrans were employed (Mw 10,
20, 40, 70, and 150 kDa). A volume of 10 lL of microcapsule
suspension (170 capsules) was washed and a 0.5mg/mL
FITC-dextran solution was added. Samples were incubated at
room temperature for 24 h and observed by confocal micros-
copy (Leica TCS SP2 AOBS Spectral Confocal Scanner (Buffalo,
NY) mounted on a Leica DM IRE2 inverted fluorescent micro-
scope, Wetzlar, Germany). Micrographs were analyzed using
ImageJ. Equal area squares were defined and the relative
intensity of 20 microcapsules and 20 background areas was
determined to obtain the dextran diffusion percentage. Per
study group four independent samples were assayed.
2.10. Crosslinking ion determination
Microcapsules with no cell load were treated with a
500 lg/mL solution of alginate lyase in order to cause their
rupture and release all the calcium forming the matrix.
A colorimetric Calcium Detection Kit (code ab102505, Abcam,
Barcelona, Spain) was employed to perform the calcium
determination. Each group was assayed in triplicate.
2.11. Cell cycle
In this method, BrdU (an analogous of the DNA precursor
thymidine) was incorporated into newly synthesized DNA.
Additionally, cells were dyed with 7-aminoactinomycin D (7-
AAD), which binds to the total DNA and resolves cell cycle
phases in our populations (G0/1 (resting phase) or S/G2/M
(DNA synthesis and division). With that purpose, cells were
previously de-encapsulated using a 500 lg/mL solution of
alginate lyase and treated using the BrdU Flow Kit Staining
Protocol (code 559619, BD Biosciences, Madrid, Spain).
Finally, three independent samples from each group were
analyzed by flow cytometry.
2.12. Animal experimentation
In vivo studies were performed according to the ethical guide-
lines established by the institutional animal care and use com-
mittee of the University of Basque Country UPV/EHU (Permit
number: CEEA_411_2015_HERNANDEZ MARTIN). Fifteen
female 6-week-old C57BL/6 mice were chosen as allogenic
immunocompetent murine models (n¼ 5 per group: bio-
logical, technological, and control). Animals were anesthesised
by isofluorane inhalation and subcutaneously implanted with
a total volume of 60 mL of microcapsules (suspended in
additional 300 mL of Dulbecco's Phosphate-Buffered Saline
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(DPBS) code BE17-513F, Lonza, O Porri~no, Spain) by means
of a 20-gauge catheter. For the control group, sole DPBS
was administered. At days 15, 30, and 45 blood samples
were collected in heparinized capillary tubes by facial vein
puncture. The obtained whole blood was centrifuged at
760 g for 15min and hematocrit levels were determined
using a standard microhematocrit method. At day 45 mice
were sacrificed. Samples were retrieved and fixed in 4%
paraformaldehyde for histological analysis. Hematoxylin and
eosin staining was performed and results were blindly eval-
uated by a pathologist.
2.13. RNA isolation, microarray hybridization, and
transcriptomic analysis
Total RNA was extracted from four independent samples of
cells within biological or technological microcapsules, using
Tri Reagent solution (Fisher Scientific, Madrid, Spain), and the
modified precipitation protocol recommended for sources
rich in polysaccharides and proteoglycans. After the addition
of 10 mg of glycogen, RNA was further purified with PureLink
RNA Mini Kit (Fisher Scientific, Madrid, Spain). RNA concentra-
tion and purity were assessed by NanoDrop 1000 spectro-
photometer (NanoDrop Technologies Inc.,Wilmington, DE)
and RNA quality and integrity were assayed by Lab-chip tech-
nology on an Agilent 2100 Bioanalyzer with Agilent RNA
6000 Nano Chips (Agilent technologies, Santa Clara, CA). All
obtained RNA samples were degraded with RNA integrity
number (RIN) values 1–2. Whole mouse gene expression
microarray analysis was performed using the available
SurePrint G3 Mouse GE v2 8x60K Microarray (Agilent
Microarray Design ID: ID 074809, Agilent Technologies, Santa
Clara, CA). Nucleic acid from each replicate, 100 ng, were
labeled following the Agilent protocol “Gene Expression FFPE
Workflow”. Feature Extraction Software version 10.7.3.1
(Agilent Technologies, Santa Clara, CA) was used to convert
the image into expression data. Raw data were preprocessed,
normalized and filtered using GeneSpring GX version 13.0
software (Agilent Technologies, Santa Clara, CA). Data were
normalized with quantile method and filtered based on
coefficient of variation (CV <100%), obtaining the log2 of the
average value of signal intensity for each probe. LIMMA stat-
istical package (Smyth, 2004) from the Multi Experiment
Viewer (MEV) software version 4.9 (GraphPad Software Inc, La
Jolla, CA) (Saeed et al., 2006) was used for differential gene
expression analysis. Conventional statistical criteria (adjusted
p value <.05) were used for the selection of differentially
expressed genes. Microarray data have been deposited in the
ArrayExpress database at EMBL-EBI (www.ebi.ac.uk/arrayex-
press) under accession number E-MTAB-5786. (For further
details, see the supplementary data).
2.14. Data analysis and statistics
To detect significant differences between two groups
Student’s t-test was used, while one-way ANOVA was chosen
for multiple comparisons. Depending on the results of the
Levene test of homogeneity of variances, Bonferroni or
Tamhane post-hoc test was applied. For non-normally distributed
data, Mann-Whitney nonparametric analysis was applied. All
statistical computations were performed by SPSS 23 (IBM SPSS,
Chicago, IL). Data are shown as mean± SD.
3. Results
3.1 Characterization of the solutions
To determine the influence of selecting inert or electrolyte
osmolarity adjusting agents, two sets of solutions were
designed: a biological set (containing electrolytes as osmolarity
adjusting agents) and a technological set (with mannitol as an
inert agent). During the design, preliminary experiments were
performed to determine the best vehicle containing electro-
lytes for the biological 1.5% alginate solution. Among DMEM
w/o Caþ2 and Mgþ2, hanks balanced salt solution (HBSS) and
phosphate buffered saline (PBS), the former was selected.
Despite presenting osmolarity values slightly above the limits,
it was chosen for providing the best results regarding cell via-
bility and metabolic activity (Supplementary Figure S2). The
resulting sets were characterized (Table 1) showing physio-
logical pH and osmolarity values.
3.2. APA microcapsules formulated with different types
of osmolarity adjusting agents led to contrasting cell
behavior in vitro
The biological and technological sets of solutions were
employed to encapsulate D1-MSCs-EPO, obtaining biological
Table 1. Characterization of the biological and technological sets of solutions. Composition, pH, and osmolarity (mOsm/L).
Solution Composition pH Osmolarity (mOsm/L)
Biological set
1.5% Alginate 1.5% alginate, DMEM w/o Ca2þ, Mg2þ 8.01 ± 0.30 345 ± 17
0.05% PLL 0.05% PLL, DPBS w/Ca2þ, Mg2þ 7.23 ± 0.05 277 ± 14
0.1% Alginate 0.1% alginate, DPBS w/Ca2þ, Mg2þ 7.12 ± 0.04 282 ± 16
100mM CaCl2 100mM CaCl2, 25mM HEPES buffer, 0.7% mannitol, ddH2O 7.04 ± 0.05 284 ± 17
Washings CaCl2 to 2.5mM calcium, DPBS w/Ca
2þ, Mg2þ 7.13 ± 0.04 286 ± 06
Technological set
1.5% Alginate 1.5% alginate, 25mM HEPES buffer, 4.3% mannitol, ddH2O 7.22 ± 0.16 305 ± 07
0.05% PLL 0.05% PLL, 25mM HEPES buffer, 4.7% mannitol, ddH2O 7.20 ± 0.10 289 ± 11
0.1% Alginate 0.1% alginate, 25mM HEPES buffer, 4.7% mannitol, ddH2O 7.09 ± 0.04 306 ± 04
100mM CaCl2 100mM CaCl2, 25mM HEPES buffer, 0.7% mannitol, ddH2O 7.04 ± 0.05 284 ± 17
1 Washing CaCl2 to 2.5mM calcium, 25mM HEPES buffer, 4.5% mannitol, ddH2O 7.06 ± 0.10 292 ± 03
Rest of washings 25mM HEPES buffer, 4.8% mannitol, ddH2O 7.10 ± 0.02 292 ± 06
Each value represents mean ± SD (n ¼ 3). DMEM: Dulbecco’s modified Eagle’s medium; PLL: poly-L-Lysine; DPBS: Dulbecco's phosphate-buffered saline; HEPES –
N0-2: hydroxyethylpiperazine-N0-2 ethanesulphonic acid; ddH2O: deionized water.
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and technological microcapsules, respectively. In order to
study cell behavior within each group, microcapsules were
cultured in vitro for 45 d. During the course of the study,
important cell-aggregates started to emerge in technological
microcapsules, fact that was not so evident in the biological
group (Figure 1(A)). Their area was quantified confirming sig-
nificant differences from day 21 (p< .001) (Figure 1(B)). BrdU
uptake assays supported these data by demonstrating that
the proliferation rate remained constant in the biological
group whereas it showed important variations for techno-
logical microcapsules.
In particular, for the latter, cell division significantly
increased by day 30 (p< .001) but drastically decreased
by day 45 (Figure 1(C)). This drop at the end of the
study may be originated by reduced cell viability, as shown
in calcein/ethidium fluorescent micrographs (Figure 1(A)).
This phenomenon was also observed in flow cytometry ana-
lysis (Figure 1(D)). Although the number of viable cells per
mL of capsules increased in both groups over the study,
Biological microcapsules adjusted to a linear tendency
(R2¼ 0.981), whereas the technological group followed an
exponential one (R2¼ 0.997) (Figure 1(D)). Nevertheless, by
day 45, the latter withdrew from its trend, pointing out,
again, to increased cell death. The exact same profiles were
obtained for cell metabolism (Figure 1(E)) and therapeutic
factor production (Figure 1(F)).
3.3. Mechanical studies revealed relevant differences in
the structural properties
To determine if the incorporation of different types of osmo-
larity adjusting agents influenced the configuration of the
Figure 1. APA microcapsules formulated with different types of osmolarity adjusting agents led to contrasting cell behavior in vitro. (A) Bright field and LIVE/DEAD
fluorescence micrographs taken at different time points after cell encapsulation revealed diverging cell behavior. (B) Subsequent quantification of cell-aggregate
areas demonstrated statistically significant differences. (C) Bromodeoxyuridine (BrdU) uptake studies confirmed these data by showing an important increase in pro-
liferation in the technological group by day 30. Consequently, the biological biosystem presented a linear tendency for cell viability (D), metabolic activity (E), and
erythropoietin (EPO) production (F), whereas technological capsules followed an exponential trend up to day 30. From that point on, this group withdrew from its
tendency due to an increase in cell death. Line graphs symbolize mean ± SD (n¼ 5 for BrdU uptake, n¼ 3 for cell viability, and EPO production studies, n¼ 7 for
metabolic assays). Statistical significance: p< .05, p< .01 and p< .001. Scale bars¼ 400 mm.
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capsule, mechanical studies were performed. When compar-
ing biological versus technological beads (microspheres with
no coatings), larger diameters were observed in the latter
(p< .001) (Figure 2(A)). Subsequently, the diameters of
coated microcapsules (APA microcapsules) were analyzed,
obtaining, again, higher values for the technological group
(p< .001) (Figure 2(B)). In order to elucidate if the increase in
size was only due to the core solution (1.5% alginate) or on
the contrary, to a synergistic effect between core and coating
solutions (0.05% PLL and 0.1% alginate), biological microcap-
sules were compared to hybrid capsules (biological core and
technological coatings). Hybrid particles presented larger size
(p< .001) (Figure 2(C)) confirming the direct effect of both
core and coating solutions in the size of the capsule.
We next evaluated the osmotic resistance by performing
ddH2O washings. Higher swelling values were observed in
the biological group when compared to technological
(p< .05) (Figure 2(D)) or hybrid microcapsules (p< .001)
(Figure 2(E)). The number of broken capsules after each
washing was also quantified (Figure 2(F)). For the biological
group, a 40% of the microcapsules broke in the second
washing, while the rest exploded in the third. Contrarily,
both technological and hybrid microcapsules presented a
slightly higher resistance: around a 40% exploded in the third
washing, and the remaining did it in the fourth. Concerning
permeability, confocal fluorescent micrographs
(Supplementary Figure S3) revealed that the FITC-dextran dif-
fusion presented no statistical differences in the MWCO
(Figure 2(G)). To finish with the mechanical characterization,
the calcium-mediated crosslinking of the alginate matrix was
analyzed. A significantly higher release of calcium from bio-
logical matrices (p< .05) suggested they contained a greater
concentration of the divalent ion, and consequently, a higher
crosslinking degree (Figure 2(H)).
Figure 2. Mechanical studies revealed important differences in the structural properties of microcapsules. Diameter quantification of uncoated beads (A), alginate-
poly-L-lysine-alginate (APA) microcapsules (B) and a comparison between biological and hybrid microcapsules (biological core and technological coatings) (C). In all
cases, greater sizes were observed when employing technological solutions. Osmotic resistance was assessed for APA microcapsules (D) and a comparison between
biological and hybrid microcapsules (E) and both showed an increased swelling behavior for the biological group. (F) Despite the three types of microcapsules pre-
sented a good resistance to rupture, it was enhanced in the hybrid and technological groups. (G) FITC labeled dextran diffusion showed no differences in permeabil-
ity. (H) Calcium release assays proved a higher crosslinking degree in biological matrices. Graphs symbolize mean ± SD (n¼ 30 for diameter quantification and
osmotic resistance, n¼ 3 for calcium determination assays, n¼ 4 for FITC dextran diffusion). Statistical significance: p< .05, p <.01, and p< .001.
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3.4. Cell cycle analysis demonstrated that the
mechanical differences led to differing cell behavior
in vitro
Since the mechanical characterization of microcapsules deter-
mined a higher crosslinking degree in the biological matrix,
we hypothesized this may be the factor which controlled the
aggregate formation in this group. To shed light on this
issue, we studied simultaneously cell cycle and proliferation.
At day 1 after encapsulation, the majority of cells in both
groups presented an S/G2/M state with no BrdU uptake
(63.3% for biological and 66.1% for technological)
(Figure 3(A)). According to these results, before the addition
of BrdU cells had already duplicated their genetic material
and invested the following 48 h, in presence of BrdU, in the
step previous to cell division.
At day 30, the majority of cells in both groups presented
a G0/1 state with no BdrU uptake (55.3% for biological and
57.9% for technological) (Figure 3(B)). However, interesting
differences were observed in the remaining states. The bio-
logical group followed a similar pattern in comparison to day
1, having the highest percentage of those remaining cells in
S/G2/M state with no BrdU uptake. Nevertheless, the trend
changed for the technological group. The majority of the
remaining cells presented a G0/1 state with BrdU uptake.
Therefore, after the addition of BrdU cells duplicated their
genetic material (incorporating BrdU), and divided, thereby
completing the cell cycle. Thus, for this group, cell division
occurred in a remarkably shorter period of time. A schematic
representation is depicted in Figure 3(C).
3.5. In vivo studies exhibited divergent therapeutic
profiles
In order to assess the therapeutic effect in vivo, biological
and technological microcapsules were implanted in C57BL/6
mice for 45 d. The biological group showed progressive
increases in hematocrit levels, with narrowed distribution.
Contrarily, technological microcapsules showed erratic pro-
files with high dispersion values (Figure 4(A,B)). Once
the implants were retrieved, microscopic observation
demonstrated that biological microcapsules maintained
their spherical shape and integrity, but the vast majority
of technological capsules were broken and released their
load in form of enormous cell-aggregates (Figure 4(C)).
Although cell-aggregates were also observed in the bio-
logical group, their size was significantly smaller (p< .001)
(Figure 4(D)).
The hematoxylin and eosin staining revealed that all
implants in the biological group showed a similar behavior;
contrasting with technological implants, where the two grafts
that failed to raise the hematocrit levels showed empty
microcapsules (Figure 4(E.I)). The inflammatory response was
remarkably more intense in the technological group (Figure
4(E.II)), except for the two implants showing capsules with no
cell load (Figure 4(E.I)). Moreover, technological micro-
capsules showed enormous cell-aggregates, which caused
mesenchymal micro tumors (Figure 4(E.III)). Broken capsules
were observed in the technological group (Figure 4(E.IV)).
This fact led to the release of the cellular content and subse-
quent inflammatory response. The rupture together with the
aggressive proliferative capacity of this group caused cell
migration and extracapsular tumor-like mass formation
(Figure 4(E.V)). Such behavior was not observed in the bio-
logical group, were microcapsules maintained their integrity
(Figure 4(E.VI–X).
3.6. Behavioral differences were caused at a genic level
For gene expression studies, four independent samples of
cells within each type of matrix were analyzed. One techno-
logical replicate was removed from this expression analysis
due to technical problems during the hybridization with the
microarray. Our study recovered a set of 1570 genes with sig-
nificant changes (p< .05) in expression. In particular, we
focused on differentially expressed genes showing a FC >3
or <3. Under such restriction, cells within technological
microcapsules showed 176 up-regulated and 88 down-regu-
lated genes versus the biological group (Supplementary
Table 1). It is noteworthy that 86 out of the 264 sequences
presented unknown function.
Among the rest, many of these genes pointed out to a
higher activation of proliferative pathways in the techno-
logical group (Figure 5). Such is the case of the PI3K/Akt/
mTOR pathway, where the up-regulation of genes such as
Gnb3 (FC 3.51), Pik3cg (FC 3.65), and Igbp1b (FC 6.01)
together with the down-regulation of Inpp5d (FC 3.48) pro-
moted this route. Similarly, the Ras/Raf/MAPK pathway was
reinforced due to the up-regulation of Ros1 (FC 6.05) or
Cyp2c44 (FC 5.34) genes. Additionally, the higher expression
of Usp2 (FC 3.03) and Usp17le (FC 6.06), together with the
down-regulation of transcriptional co-repressors such as
Basp1 (FC 3.7) led to cell cycle progression.
The reorganization of the cytoskeleton was also enhanced
in the technological group due to the up-regulation of genes
such as Rhoj (FC 4.46) or Eps8l1 (FC 3.72). Furthermore, the
technological group showed up-regulation of the Adamts16
gene (FC 6.77), suggesting chondrogenic differentiation. On
the contrary, the biological group presented a high expression
of Col12a1 (FC 11.96), gene present in the osteogenic differ-
entiation. Finally, the Ptprd (FC 3.18) and Ptprr (FC 3.25)
tumor suppressor genes showed a lower expression in tech-
nological cells, whereas the Hspa12a heat shock protein was
significantly up-regulated (FC 3.09).
4. Discussion
Currently, there is an urgent need to regulate cell behavior
in encapsulation systems, since the lack of control leads to
unsuccessful therapies and represents an important hurdle
toward clinical translation (Bhujbal et al., 2014; Gonzalez-
Pujana et al., 2017). Interestingly, the stiffness of the matrix
has been described to play an important role in the regula-
tion of cell responses (Shin & Mooney, 2016). Therefore, to
date, many have been the attempts to modulate this factor.
Nonetheless, little attention has been paid to the osmolarity
adjusting agents as a tool to regulate the final outcome of
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the therapy. Considering that microcapsule formation occurs
by electrostatic interactions, this process is directly influenced
by the presence of electrolytes, especially divalent cations, in
the surrounding media (Chen et al., 2014; Thu et al., 1996).
Hence, we hypothesized that in the attempt to design solu-
tions that meet the standards for cell culture, the choice of
different types of osmolarity adjusting agents may play a
pivotal role in the mechanics of the capsule. To shed light on
Figure 3. Cell cycle analysis demonstrated that the mechanical differences led to differing cell behavior in vitro. (A) Flow cytometry combining bromodeoxyuridine
(BrdU) uptake and 7-aminoactinomycin D (7-AAD) staining showed no statistically significant differences at the very beginning of the study. (B) This tendency dra-
matically changed by day 30, where the proliferation rate of the technological group significantly increased. (C) Schematic representation of the results obtained in
the combined flow cytometry assay at day 30. In particular, the scheme shows the proliferative capacity of the remaining cells that do not present a G0/1 state
(44.7% biological, 42.1% technological). Graphs symbolize mean ± SD (n¼ 3). Statistical significance: p< .05.
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this premise, two different sets of solutions were designed.
Both of them were adjusted to adequate osmolarity values,
however, different types of osmolarity adjusting agents were
selected to do so. For the biological set of solutions,
electrolytes such as sodium, potassium, calcium, or phos-
phates were chosen. Contrarily, mannitol was included as an
inert agent in the technological set of solutions (Table 1).
Subsequently, D1-MSCs-EPO was encapsulated using these
Figure 4. In vivo studies exhibited divergent therapeutic profiles. (A) Hematocrit levels increased progressively in a controlled fashion for all biological implants but
showed an erratic trend with a big data dispersion for the technological group (B). (C) Morphological characterization after graft explantation revealed enormous
cell-aggregates and broken capsules in the technological group. (D) Cell-aggregate area quantification proved statistically significant differences between the
groups. (E) The histological studies showed empty microcapsules for the technological implants that failed (I). The analysis also confirmed that technological
implants presented an intense inflammatory response (II), cell-aggregates causing microtumors (III), capsule rupture (IV), and the consequent extracapsular tumor
formation (V). Such behavior was not observed in biological implants, where a lower inflammation (VI–VII) and capsule integrity with no cell extravasation (VIII–X)
were observed. Graphs symbolize mean ± SD. (n¼ 5 for animal studies, n¼ 30 for diameter quantification). For the control group sole DPBS was administered.
Statistical significance: (A) Between Control and Biological groups: p< .01 and p< .001, between Control and Technological groups: ###p< .001; (D)p< .001. Scale bars: (C)¼ 400 mm; (E) I, II, VI, VII ¼400 mm; III, IV, V, VIII, IX ¼100 mm; X¼ 50 mm.
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sets, obtaining biological or technological microcapsules. This
cell type was selected because of its aggressive proliferative
capacity (Garate et al., 2015; Gurruchaga et al., 2015), which
renders it a suitable model for studying the control that the
mechanical configuration of the matrix may exert on cell
behavior. Indeed, during the course of our study, these cells
were able to proliferate even in starving conditions
(Supplementary Figure S4).
Figure 5. Gene expression studies proved that the behavioral differences were caused at a genic level. (A) Schematic representation of signaling pathways in which
gene expression presents a fold change> 3 or< 3 in cells within technological microcapsules, in comparison to the biological group. (B) Heat map representation
of differentially expressed genes. Results are expressed as a fold change ratio. Each column represents a replicate and each row represents a gene (Euclidean dis-
tance, average linkage; n¼ 4 for gene studies, with the loss of a technological replicate due to technical problems during hybridization process. B: biological; T:
technological). (C) Values of fold change in cells within technological vs. biological capsules. In all cases, red color indicates up-regulated genes and green color
down-regulated genes.
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Firstly, pivotal differences were observed when evaluating
cell behavior in vitro (Figure 1). The morphological analysis,
together with the BrdU uptake assay showed a significantly
higher proliferation rate in the technological group, with the
subsequent cell-aggregate formation (Figure 1(A–C)). These
results could explain the so different tendencies that cells
repeatedly followed in viability, metabolism and EPO secre-
tion studies: linear for biological and exponential for techno-
logical microcapsules (Figure 1(D–F)). Moreover, regarding
the technological group, the dramatic decrease of
proliferation and the failure in the exponential trend by day
45 were probably caused by a decrease in viability (Figure
1(A,D)). We point out to the enormous aggregates as the
most probable factor that originated cell death, possibly due
to pore collapse (Leal-Egana et al., 2012), and subsequent
limited diffusion of oxygen and nutrients to the inner core.
In order to determine if the contrasting cell behavior was
originated by differences in the mechanical properties of the
system, structural studies were carried out. Most importantly,
these studies revealed significant differences in matrix
configuration. Considering that the binding between the
alginate and the crosslinking ion is responsible for conferring
stiffness to the matrix, higher calcium levels, and thus a
higher crosslinking degree, suggested a less permissive
matrix in biological capsules (Figure 2(H)). According to these
results, during the coating process, the calcium loss was
lower when beads were put in contact with solutions that
presented it, probably due to the gradient stabilization that
could have prevented the leakage. Consequently, biological
microcapsules retained more calcium, whereas the techno-
logical group presented a higher leakage of the ion, resulting
in a more permissive matrix (Kleinberger et al., 2013; Ma
et al., 1994). This property allowed an aggressive proliferation
in the latter, leading to the formation of huge cell-aggre-
gates. On the contrary, the more restrictive matrix of bio-
logical microcapsules established a control in cell division
(Richardson et al., 2016; Liu et al., 2015). Therefore, it was not
the direct effect of osmolarity adjusting agents on cells which
evoked so contrasting behavior, but the effect this agents
have in the capsule formation process and thus, in the final
crosslinking degree of the alginate matrix.
Calcium determination may also explain the results
obtained for particle size. When capsules were put in contact
with technological solutions, the calcium loss not only led to
a decreased stiffness, but also to swelling, thus increasing
microcapsule diameter (Figure 2(A–C)) (Kleinberger et al.,
2013). Additionally, a higher osmotic resistance in techno-
logical microcapsules suggested an enhanced interaction
between the alginate matrix and the PLL coating (Figure
2(D–F)). This may have been caused by the contribution of
two phenomena. Firstly, technological microcapsules pre-
sented less calcium in their matrix (Figure 2(H)), and conse-
quently, a higher number of alginate chains were free to
interact with the PLL. Secondly, since the membrane forma-
tion is governed by electrostatic interactions between the
alginate and the polycation, the presence of ions in the
surrounding media may weaken the bind (Thu et al., 1996).
Therefore, although both groups presented a good osmotic
resistance, it was enhanced in the technological group.
Regarding permeability, no statistical differences were
observed, with both groups maintaining an adequate MWCO
to fulfill the objectives of the technology (Figure 2(G)).
To thoroughly evaluate the effect of the matrix crosslinking
degree in cell division, next step was to study in depth cell
cycle. The proliferation rate was remarkably enhanced for
technological microcapsules by day 30 (Figure 3(A,B)).
Although a 55.3% of biological and a 57.9% of technological
cells presented a G0/1 state, interesting proliferative differen-
ces were detected in the remaining cells. Specifically, a signifi-
cant number of cells in the biological group remained the 48h
after BrdU addition in the same S/G2/M state they were before
inclusion of the thymidine analog. Contrarily, the technological
group was able to duplicate the genetic material and com-
plete the cycle, returning to G0/1 phase with the BrdU label
incorporated in the DNA. This indicates that softer matrices
present lower resistance to deformation, allowing a signifi-
cantly faster cell division (Figure 3(C)) (Leal-Egana et al., 2012).
Because the in vivo studies represent the most similar
approach to clinics, they were pivotal to determine if the
obtained data remained significant. Concerning hematocrit
profiles (Figure 4(A)), biological microcapsules showed a pro-
gressive increase, obtaining similar values for every mouse in
the group. Nevertheless, by day 30, two of the technological
implants had already failed, and the remaining showed
important data dispersion (Figure 4(B)).
When morphologically analyzing the explants after 45 d of
study, great differences were observed (Figure 4(C)).
Important cell-aggregates were detected in technological
microcapsules and their size quantification confirmed, once
again, the divergent proliferation rates in each group (Figure
4(D)). Moreover, while biological microcapsules remained
spherical and maintained their integrity, for the technological
group, the majority of capsules were broken, allowing
the cell content to be released to the surrounding tissue
(Figure 4(C)). That was probably originated by the enormous
aggregates whose aggressive growth triggered an increment
in pressure that was not tolerated by the membranes of the
system. Histological analysis supported these results by
showing a significantly higher capsule rupture in the techno-
logical group, which resulted in tissue invasion and tumor-
like mass formation (Figure 4(E.III–V)). This fact may have also
contributed to the severe inflammatory response observed in
such group (Figure 4(E.I–II)). In particular, dying cells released
from technological microcapsules might have secreted
DAMPs, which are extensively recognized to play a role in
the responses against grafts (Paredes Juarez et al., 2014).
The final goal of cell microencapsulation technology is to
maintain the bioactive factor levels within the therapeutic
range in a sustained manner. Since biological implants pro-
vided progressive increases with minimal dispersion values,
they were able to fulfill this objective and give rise to a con-
trolled regimen. On the contrary, the erratic behavior shown
by cells encapsulated within technological microcapsules led
to an unpredictable secretion of EPO. Indeed, some implants
failed and others maintained their functionality, making it dif-
ficult to foretell the result of the therapy. Moreover, it may
be hypothesized that in the functional technological
implants, due to the extreme proliferation rate allowed by
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such type of matrix, hematocrit levels may continue to
increase, reaching toxic levels.
Microarray analysis explained that the contrasting cell
behavior observed was due to differences at a genic level.
Important proliferative pathways were significantly activated
in cells enclosed within technological microcapsules. The up-
regulation of genes such as Gnb3, Pik3cg, or Igbp1b together
with the down-regulation of Inpp5d, enhanced the PI3K/Akt/
mTor route. Similarly, the Ras/Raf/MAPK pathway was pro-
moted due to over-expression of genes like Ros1 (Chin et al.,
2012) and Cyp2c44, which can also activate Akt (Yang et al.,
2009). Interestingly, it has been reported that when these
two pathways are mutated or amplified, proliferation, and
survival signals are constitutively activated and, ultimately,
lead to tumorigenesis (Wu et al., 2017). Additionally, the
over-expression of Ros1 might give rise to reorganization of
the cytoskeleton, process often related to metastasis and
migration (Chin et al., 2012). This effect may have been
accentuated by the up-regulation of other implied genes
such as Rhoj, which can evoke focal adhesion disassembly
(Wilson et al., 2014), and Eps8l1, which can activate Rac,
leading to the reorganization of the actin cytoskeleton
(Offenhauser et al., 2004). Moreover, cell cycle arrest may
have been repressed due to the up-regulation of Usp2 and
Usp17le, since they promote the stabilization of cyclin D1
(Shan et al., 2009) and Cdc25A (Hjortland & Mesecar, 2016),
respectively. Supporting these results, Ptprd and Ptprr tumor
suppressor genes were down-regulated in the technological
group. The expression of the former can inhibit the Stat path-
way, which leads to proliferation and survival (Ortiz et al., 2014).
The latter, is able to inhibit MEK, repressing the Ras/Raf/MAPK
route (Su et al., 2013). Furthermore, for the same group, we
found up-regulation of Hspa12a, whose high expression has
been proven in tumor tissues (Yang et al., 2015). Consequently,
cells enclosed in technological microcapsules may have found
less restriction to develop a tumor-like behavior.
Genes related to differentiation of D1-MSCs-EPO into other
lineages presented a distinctive expression. In particular, we
observed an up-regulation of Col12a1 in biological microcap-
sules. This gene encodes type XII collagen, which is expressed
by osteoblasts and localizes to areas of bone formation (Izu
et al., 2011). On the other hand, the Adamts16 gene, up-regu-
lated in technological cells, has been reported to be
expressed by MSCs during chondrogenesis (Boeuf et al.,
2012). These differences may be explained by the already
described mechanosensitive differentiation of MSCs by which,
according to the physical properties of each matrix, cells dif-
ferentiate into varying lineages (Rape et al., 2015).
Considering all these evidences, it is possible to determine
that gene expression was considerably influenced by the
mechanical characteristics of the matrix in which cells were
encapsulated. The pivotal differences regarding expression
resulted in a contrasting cell behavior both, in vitro and in
vivo. Since in our system cells are responsible for producing
the therapeutic factor, there is a direct connection between
cell behavior and drug delivery. Therefore, the different cell
responses had a drastic impact on the release of the thera-
peutic factor, influencing key points such as the efficacy and
safety of the therapy. Therefore, our research supports the
data described in the literature pointing out to a mechano-
sensing process in the absence of integrin binding domains
(Huang et al., 2013; Bhujbal et al., 2014). Further research
should focus on the mechanism by which it occurs in order
to gain knowledge over the factors involved in cell-micro-
environment interactions.
5. Conclusion
The present work provides new insights regarding the regula-
tion of uncontrolled cell responses in alginate microspheres. In
particular, we proved the employment of osmolarity adjusting
agents as a useful tool to modify the mechanical configuration
of the matrix, with no need of altering the biomaterial or cross
linker type/proportion. Technological microcapsules, resulting
from the employment of inert osmolarity adjusting agents,
presented a permissive matrix that allowed uncontrolled cell
division, with the subsequent erratic and dysfunctional thera-
peutic regimen. Contrarily, when employing electrolytes,
including calcium or sodium, as osmolarity adjusting agents,
biological capsules were formed. This type of matrix allowed
establishing a tight control over cell proliferation, avoiding the
enormous cell-aggregate formation, the risk of cell protrusion,
the intense inflammatory response and the potential toxicity
given by drug overdose. Overall, these data demonstrated
that employing the biological formulation represents a valuable
strategy to control cell behavior and thus achieve a predictable,
safe and controlled de novo release of therapeutics.
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